EC Number   |
Protein Variants |
Reference |
|---|
   2.7.11.18 | A27F/A29R/A31R/A32F |
mutant enzyme with defective ATP binding site, mutant leads to nearly unaltered MLC phosphorylation activity and altered morphology in transfected CV1 cells |
662502 |
| 2.7.11.18 | A983P |
dramatic increase in Ca2+ required for half-maximal activity |
640661 |
| 2.7.11.18 | A986P |
significantly increase in Ca2+ required for half-maximal activity, slightly decreased KM for regulatory light chain |
640661 |
| 2.7.11.18 | H21P |
naturally occuring single nucleotide polymorphism increasing the risk for acute lung injury within 5 das of traumatic insult |
686236 |
| 2.7.11.18 | M968P |
10% Ca2+/calmodulin independent activity of total activity, decreased KM for regulatory light chain |
640661 |
| 2.7.11.18 | more |
an antisense morpholino oligonucleotide is designed to induce mis-splicing of exon 9 of im:7148400 and early termination of the transcript before its kinase domain |
-, 740793 |
| 2.7.11.18 | more |
construction of 1-AMPK knock-out mice |
687732 |
| 2.7.11.18 | more |
construction of a dominant-negative MLCK mutant |
675010 |
| 2.7.11.18 | more |
construction of an enzyme mutant MLCK1745 which lacks the C-terminal amino acids including the autoinhibitory domain, and the myosin- and the calmodulin-binding sites, the MLCK1745 mutant increases the TNFalpha response to upregulate NFkappaB activity in transfected endothelial cells, MLCKATPdel mutant enzyme with defective ATP binding site inhibits TNFalpha-induced NFkappaB-activation activity in transfected endothelial cells |
662503 |
| 2.7.11.18 | more |
construction of an enzyme mutant MLCK1745 which lacks the C-terminal amino acids including the autoinhibitory domain, and the myosin- and the calmodulin-binding sites, the MLCK1745 mutation leads to increased growth rates of transfected CV1 fibroblasts and an increase in basal level MLC phosphorylation compared to untransfected cells, stress fiber formation is unaffected by the mutation |
662502 |
